A Controlled Safety and Preliminary Efficacy Study of the V406 Port Delivery System in the Treatment of Choroidal Neovascularization Due to Age-Related Macular Degeneration

Trial Profile

A Controlled Safety and Preliminary Efficacy Study of the V406 Port Delivery System in the Treatment of Choroidal Neovascularization Due to Age-Related Macular Degeneration

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Jan 2017

At a glance

  • Drugs Pazopanib (Primary) ; Ranibizumab
  • Indications Choroidal neovascularisation
  • Focus Therapeutic Use
  • Sponsors ForSight VISION4
  • Most Recent Events

    • 10 Jan 2017 This trial was being conducted by ForSight VISION4. The Company has now been acquired by Roche, according to a ForSight VISION4 media release.
    • 30 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top